Clinical Trials List
2016-08-01 - 2024-12-31
Phase III
Terminated5
ICD-10C61
Malignant neoplasm of prostate
-
Trial Applicant
PPD DEVELOPMENT (HK) LIMITED
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- 劉詩彬 Division of Urology
- 葉亭均 Division of Urology
- 陳育青 Division of Radiology
- - - Division of Urology
- Yu-Chieh Tsai Division of Hematology & Oncology
- 戴逸昇 Division of Urology
- CHING-CHU LU Division of Nuclear Medicine
- CHUNG-HSIN CHEN Division of Urology
- Ying-Chun Shen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Audit
None
Co-Principal Investigator
- 洪啟峰 Division of Urology
- 熊小澐 Division of Radiology
- Cheng-Kuang Yang Division of Urology
- 裘坤元 Division of Urology
- Shian-Shiang Wang Division of Urology
- 蔡世傳 Division of Nuclear Medicine
- Chuan-Shu Chen Division of Urology
- Chia-Yen Lin Division of Urology
- Cheng-Che Chen Division of Urology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Hsiao-Jen Chung Division of Urology
- 朱力行 Division of Nuclear Medicine
- Yi-Hsiu Huang Division of Urology
- Tzu-Ping Lin Division of Urology
- 沈書慧 Division of Radiology
- Tzu-chun Wei Division of Urology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Tsung-Yi Huang Division of Urology
- Hsiang Ying Lee Division of Urology
- 黃俊農 Division of Urology
The Actual Total Number of Participants Enrolled
0 Terminated
Taiwan National PI
Co-Principal Investigator
- 劉忠一 Division of Hematology & Oncology
- Jing-Ren Tseng Division of Nuclear Medicine
- Rita cheng Division of Hematology & Oncology
- 張英勛 Division of Hematology & Oncology
- 黃成之 Division of Radiology
- Yung-Chang Lin Division of Hematology & Oncology
- 沈鼎文 Division of Radiology
The Actual Total Number of Participants Enrolled
7 Terminated
Audit
None
Co-Principal Investigator
Audit
None
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
50 participants
-
Global
1100 participants
